热门资讯> 正文
雅培推出“SimpleScreen”血液检测以扩大癌症筛查
2026-09-30 20:35
- 雅培(ABT) 0
- Freenome(FRNM) 0
- 精密科学(EXAS) 0
- Abbott Laboratories (ABT) announced on Wednesday that it launched SimpleScreen CRC in the U.S., an FDA-approved blood test to screen for colorectal cancer in adults 45+ at average risk.
- The test, developed by Freenome, gives doctors another screening option alongside Abbott’s Cologuard Plus stool test.
- In a study of more than 48K adults, SimpleScreen CRC detected about 8 in 10 (81.1%) colorectal cancers and correctly ruled out advanced colorectal disease in about 9 in 10 people (90.4%).
- Medicare covers the test, with eligible Medicare Part B patients paying no out-of-pocket costs.
- Source: Press Release
More on Abbott Laboratories
- Abbott Laboratories: A Strong Business At A Fair Price
- Abbott: Quality Remains, But Exact Sciences Has Raised The Bar For Buy
- Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade)
- Abbott partners with Berry Street to provide nutrition coaching to Lingo users
- 10 large and mega-cap U.S. healthcare stocks with the weakest momentum grades
推荐文章
丘盛一筹 | 特朗普拒绝加监管！马斯克、黄仁勋集体预警：电力，才是AI的终极天花板
休市提醒：国庆假期将至，港股10月1日休市、10月2日复市；美股正常开市
华盛早报 | 重磅利好！房贷贴息新政下月落地；美联储“三把手”称10月不急于加息；欢创科技今日上市，昨日暗盘飙升近200%
美股前瞻 | 医药巨头豪掷20亿美元入股抗癌药企SMMT！特朗普释放美伊谈判利好；贝壳盘前巨震10%！房贷贴息政策重磅落地
苹果年内大涨约25%，市值迫近5万亿美元！资金风向生变，AI+折叠屏双重催化，果链哪些标的还能上车？
资金复盘 | 北水净买入港股近1500万港元，分别净买入友邦保险逾8亿、小米近4亿港元，沽出康方生物逾5亿港元
新股暗盘 | “大肉签”再现！欢创科技大涨近130%，中签一手赚超7500港元！
华盛早报 | 股债性价比反转！10年美债吸引力超标普500指数；英伟达狂撒1500亿美元回购逆势上升；Anthropic25财年营收飙升1088%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
